Drug developer Praxis Precision Medicines announced an underwritten public offering of its common shares and pre-funded warrants. The offering includes 55.2 million common shares and pre-funded warrants to purchase up to 7.1 common shares. With a price set at USD 0.95 per share, the company aims to raise approximately USD 59.1 million.
Additionally, the company has also granted the underwriters a 30-day option to purchase an additional 9.3 million shares at the same price. The offering is expected to close on June 21, 2023, and the use of net proceeds was not disclosed.
The capital raised from this offering will likely support Praxis Precision Medicines' ongoing operations and strategic initiatives, furthering the development of its pipeline and potential future endeavors.
The public offering is being facilitated by Piper Sandler and Truist Securities, who are serving as the joint book-running managers for the offering.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.